Your browser doesn't support javascript.
loading
Ligand-directed signalling within the opioid receptor family.
Pradhan, Amynah A; Smith, Monique L; Kieffer, Brigitte L; Evans, Christopher J.
Afiliación
  • Pradhan AA; Semel Institute for Neuropsychiatry & Human Behavior, University of California Los Angeles, Los Angeles, CA 90024-1759, USA. amynahpradhan@ucla.edu
Br J Pharmacol ; 167(5): 960-9, 2012 Nov.
Article en En | MEDLINE | ID: mdl-22708627
The classic model of GPCR activation proposed that all agonists induce the same active receptor conformation. However, research over the last decade has shown that GPCRs exist in multiple conformations, and that agonists can stabilize different active states. The distinct receptor conformations induced by ligands result in distinct receptor-effector complexes, which produce varying levels of activation or inhibition of subsequent signalling cascades. This concept, referred to as ligand-directed signalling or biased agonism has important biological and therapeutic implications. Opioid receptors are G(i/o) GPCRs and regulate a number of important physiological functions, including pain, reward, mood, stress, gastrointestinal transport and respiration. A number of in vitro studies have shown biased agonism at the three opioid receptors (µ, δ and κ); however, in vivo consequences of this phenomenon have only recently been demonstrated. For the µ and δ opioid receptors, the majority of reported ligand selective behavioural effects are observed as differential adaptations to repeated drug administration. In terms of the κ opioid receptor, clear links between ligand-selective signalling events and specific in vivo responses have been recently characterized. Drugs for all three receptors are either already used or are being developed for clinical applications. There is clearly a need to better characterize the specific events that occur following agonist stimulation and how these relate to in vivo responses. This understanding could eventually lead to the development of tailor-made pharmacotherapies where advantageous drug effects can be selectively targeted over adverse effects.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Opioides Límite: Animals / Humans Idioma: En Revista: Br J Pharmacol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptores Opioides Límite: Animals / Humans Idioma: En Revista: Br J Pharmacol Año: 2012 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido